Nemaura Pharma has entered into a license agreement with a global pharma company on the development of three new Transdermal Patch products.
These patches address a multi-Billion dollar market and the agreement reflects the confidence placed in Nemaura’s ability to deliver complex dosage formulations.
Previously Nemaura developed a daily transdermal patch for a CNS indication, which successfully completed clinical studies, and ANDA subsequently submitted to the FDA.
Nemaura Pharma is a UK based specialist Biotech Company with over 20 products in development, including several complex injectables, using proprietary and differentiated delivery platforms. The Company is head-quartered in the University town of Loughborough, and has several development laboratories as well as a GMP clean room suite and IMP license for the manufacture and supply of transdermal, topical, and aseptically manufactured injectable products using gassed isolation technology.
The company will be exhibiting at CPhI Madrid between the 9th and 11th October, stand 2F63 where Nemaura will be debuting its 48 hour sustained released Diclofenac gel patch. The company’s CEO Dr Chowdhury, and Director of Strategic Alliances Dr Wessling will be present for meetings.
In 2016, Nemaura received Frost & Sullivan recognition of its advanced micro-needle capability in skin drug delivery and in this year it received the UK Medilink National Award for Drug Delivery.
Nemaura aims to be one of the leading pharmaceutical technologists in this fast growing market, which is expected to be worth over £35bn within the next 5 years.
Source: Company Press Release.